Breakout Ventures Closes $114M Fund for AI Science

Breakout Ventures has successfully closed its third and largest fund to date, securing $114 million. This new capital infusion is earmarked for early-stage companies operating at the critical nexus of artificial intelligence and scientific innovation. The firm's strategy centers on pre-seed to Series A investments, targeting ventures where founders possess deep scientific acumen, a robust engineering mindset, and the capacity for swift execution.

The latest fund attracted significant backing from new limited partners, including Jimco and Korea Omega Investment Corporation. They join a roster of returning investors such as Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, and an affiliate of LH Capital. With this latest vehicle, Breakout Ventures now oversees a total of over $230 million across its three managed funds, underscoring its growing influence in the deep tech investment arena.

Fund III is strategically positioned to target high-impact sectors. Key areas of focus include biotechnology and life sciences, healthcare and digital health solutions, advanced robotics and automation, and essential developer tools and infrastructure. A significant portion will also be directed towards AI applications within biology, such as novel drug discovery platforms, advanced diagnostics, neurotechnology, and cutting-edge materials science. Managing Partner Lindy Fishburne indicated plans to support between 17 and 20 portfolio companies, with individual investment checks anticipated to range from $500,000 to $5 million.

This latest fundraising effort builds upon Breakout Ventures' established track record. The firm previously raised a $60 million Fund I in 2017 and a $112.5 million Fund II in 2021, both dedicated to supporting science-centric startups. The firm's investment philosophy emphasizes the transformative potential of AI in accelerating scientific breakthroughs, particularly in translating complex biological insights into tangible medical advancements, rather than focusing on more generalized AI applications.

Early deployments from Fund III have already been made to three promising companies. These include Reach Industries, a developer of sophisticated robotics software for laboratory environments, an undisclosed firm leveraging computational chemistry for small-molecule drug discovery, and another entity focused on the commercialization of novel scientific technologies. These initial investments reflect the fund's commitment to backing foundational science with strong commercialization potential.

Breakout Ventures has a history of identifying and nurturing successful science-driven companies. Notable past investments include Noetik, an AI-native biotech that secured $40 million in Series A funding in 2024; Phantom Neuro, a prosthetics innovator that raised $19 million in Series A in 2025; ZymoChem, a bio-based chemicals firm that completed a $21 million Series A round in 2024; and Surf Bio, which was acquired by Halozyme for a substantial $400 million in 2025. The firm's leadership team, including Managing Partners Lindy Fishburne and Julia Moore, alongside Partners Dana Watt and Nima Ronaghi, brings a wealth of scientific and entrepreneurial expertise to its investment strategy.

The broader market for AI in scientific discovery is experiencing rapid expansion. Venture funding into AI-driven biotech and healthtech has seen significant growth, with industry reports indicating substantial year-over-year increases in capital deployed. This trend is fueled by the increasing complexity of scientific challenges and the proven ability of AI to accelerate research and development cycles, potentially reducing time-to-market for critical innovations in medicine and materials science.